Celldex to Present at Upcoming Investor Conferences

Celldex Therapeutics (NasdaqCM:CLDX) Stock Forecast & Analyst Predictions

Celldex Therapeutics (CLDX) Stock Looks Rich After Shareholder Investigation

Celldex Therapeutics: Trying To Put Its Troubled History Behind It

Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success?

Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses

Celldex Shares Rise 8% as Barzolvolimab Meets Primary Endpoints in Two Phase 3 Trials

Celldex Therapeutics' Barzolvolimab Meets Phase 3 Endpoints in Two Urticaria Trials

CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’

Celldex to Present at Upcoming Investor Conference

Celldex Therapeutics (CLDX) Stock Trades At A Premium Despite A 102% Return

CLDX Stock Down 10% After-Hours — What’s Driving The Selloff?

Is Celldex Therapeutics, Inc. (CLDX) Stock Positioned for Growth Ahead of Potential 2027 Approval?

Celldex Therapeutics (CLDX) Stock Valuation Check After Recent Share Price Momentum

Celldex Therapeutics, Inc. (CLDX) Stock Price: Nov 2 Close $29.04